Drug Profile
HTD 4010
Alternative Names: HTD-4010Latest Information Update: 13 Apr 2023
Price :
$50
*
At a glance
- Originator HighTide Biopharma
- Class Anti-inflammatories
- Mechanism of Action Transcription factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Inflammation
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 13 Apr 2023 Discontinued - Phase-I for Type 2 diabetes mellitus (In volunteers) in Australia (Parenteral) (HighTide Biopharma pipeline, April 2023)
- 13 Apr 2023 Phase-I clinical trials in Inflammation (unspecified route) (HighTide Biopharma pipeline, April 2023).
- 28 Nov 2018 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In volunteers) in Australia (Parenteral, Injection)